ライフサイエンスコーパス: s.c.

1 s.c. injection of R-DOTAP results in an IFN-dependent in

2 saline or AngII (600 ng . kg(-1) . min(-1), s.c.) for 2 weeks, during which they slowly developed hy

3 orally for 3 months and 4.5 x 10(6) IU IL-2 s.c. three times per week for 1 month.

4 nistered interferon (IFN)-alpha (20 MIU/m(2) s.c.) or saline for 4 weeks.

5 -33 signaling in skin, we administered IL-33 s.c. and monitored its effects at the injection site.

6 Comparatively, a 0.49 (s.c.), 0.60 (i.n.) and 0.81 (s.c. + mucosal boost) log(1

7 cted almost all the mice exposed to 3 LD(50) s.c. of venom.

8 y, 18 h pretreatment of rats with 6 mg/kg 6c s.c. reduces AMPH-self administration but not food self-

9 When injected into day 7 s.c. CMS4 sarcoma lesions growing in syngenic BALB/c mic

10 chondrial inhibitor rotenone (2 mg/kg/d, 7d, s.c.) induced a marked decrease in Hba-a2 and Hbb but no

11 tively, a 0.49 (s.c.), 0.60 (i.n.) and 0.81 (s.c. + mucosal boost) log(10) reduction in MTB CFU was f

12 Simultaneous injection of OTAB at a s.c. injection site remote from the sciatic nerve did no

13 LPS egress from a s.c. injection site thus occurred during many weeks and

14 cked fluorescent and radiolabeled LPS from a s.c. inoculation site to its draining lymph nodes (DLN),

15 formation compared with wild-type mice in a s.c. implantation model.

16 Each construct was evaluated in a s.c. xenograft model, using CA19.9-positive (BxPC3) and

17 to male Sprague Dawley rats after starting a s.c. infusion of METH.

18 In response to a s.c. injection of KC, aged mice recruited fewer neutroph

19 Using a s.c. murine model of Lewis Lung Carcinoma, we found that

20 wer-body adipocyte hyperplasia and abdominal s.c. adipocyte hypertrophy.

21 Average abdominal s.c. adipocyte size increased by 0.16 +/- 0.06 mug lipid

22 markers of WNT activation in human abdominal s.c. adipose tissue characterized by hypertrophic obesit

23 y), consistent with the ability of abdominal s.c. adipocytes to achieve a larger size.

24 In addition, s.c. immunization with DC1s loaded with glioma-associate

25 ab (n = 20) or placebo (n = 10) administered s.c. every 4 weeks for 12 weeks (NCT01599637).

26 Liposome administration s.c., but not i.v., induced ChgA-specific Foxp3(+) and F

27 nergistically induced regression of advanced s.c. tumors, resulting in cure of some mice and developm

28 onses were generated against AML cells after s.c., but not i.v., inoculation.

29 ponse and impaired bacterial clearance after s.c. infection with S. aureus.

30 and exiting the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hep

31 analog, could achieve glycemic control after s.c. implantation in diabetic rats, with reproducible do

32 ter i.v. administration and 13-19 days after s.c. administration.

33 , and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.

34 uction in the draining lymph node 12 h after s.c. vaccination directly correlates with downstream CD8

35 OVA-specific T cells in lipogranulomas after s.c. immunization with NP-OVA.

36 luated in vitro or in xenografted mice after s.c. or intrahepatic injection in normal and cirrhotic (

37 (SERS) nanoparticles in a living mouse after s.c. injection.

38 nodes was observed after i.d., but not after s.c., inoculations, we used the latter model as a strate

39 producing IL-17 in joint tissues only after s.c. immunization.

40 f IFN-gamma KO mice, they are rejected after s.c. transplantation.

41 olecule accumulated on B cells in vivo after s.c. administration.

42 s strain induced complete protection against s.c. challenge and partial protection (70% survival) aga

43 to induce potent antitumor responses against s.c. MC38 colon adenocarcinomas in immunocompetent mice.

44 Although s.c. treatment with testosterone and aromatase inhibitor

45 Here, rats were given an s.c. injection of either saline or choline chloride dail

46 d liberation of bioactive constituents in an s.c. rat implantation model.

47 hat modular tissue engineering results in an s.c. vascularized bed that enables the transplantation o

48 These results demonstrate that an s.c. implantation approach in a 3D carrier scaffold seed

49 her inhibition of the miR-34 family using an s.c.-delivered seed-targeting 8-mer locked nucleic acid

50 ubonic plague and compare this model with an s.c. inoculations result in faster kinetics of infection

51 rameter flow cytometry analysis in blood and s.c. WAT (SAT).

52 ng a p.v. challenge, unimmunized control and s.c.-s.c.-immunized animals developed Chlamydia-specific

53 onse in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine, all in

54 ative-control groups were immunized i.m. and s.c. with Neisseria gonorrhoeae recombinant porin B (Ng-

55 of a range of proinflammatory mediators, and s.c. injection of cholesterol sulfate results in a Mincl

56 (+) B cells decreased B16-F10 metastasis and s.c. tumor growth, and this was IFN-gamma dependent.

57 d monocytes can acquire Ag within muscle and s.c. afferent lymph, and that HBsAg-AS01 uniquely induce

58 Both p.o. and s.c. immunizations induced Chlamydia-specific serum IgA.

59 Strikingly, in both omental and s.c. WAT from BMI-matched obese humans, expression of Ci

60 ph nodes (MLN) and the spleen after i.p. and s.c. immunization.

61 ce of infection of marmosets by the i.v. and s.c. exposure routes.

62 administered at two dose levels by i.v. and s.c. injection revealed that the bioavailabilty of s.c.

63 phenotypic differences between visceral and s.c. adipocytes.

64 yte hypertrophy evident in both visceral and s.c. depots.

65 Visceral and s.c. fat exhibit different intrinsic properties, includi

66 gns were implanted in the ovine skull and at s.c. sites and retrieved after 12 and 3 mo, respectively

67 ced the anti-CNS glioma effects of DC1-based s.c. immunization.

68 us (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal boost, respectively, versus naive mice.

69 targeting were investigated in mice bearing s.c. Neuro2A tumors.

70 ant tumors were observed in A/J mice bearing s.c. NXS2 neuroblastomas treated with IT-IC compared wit

71 aint is to use noncirculating, biodegradable s.c. implants as drug carriers that are stable throughou

72 onse to overfeeding in upper- and lower-body s.c. fat depots of 28 healthy, normal weight adults (15

73 ficant inhibition in MM tumor growth in both s.c. and i.p. models and the presence of a chemotherapeu

74 ment with polyI:C can strongly suppress both s.c. implanted TRAMP tumors in syngenic mice as well as

75 patially controlled lymphocyte activation by s.c. administered antibodies in vivo.

76 trolled levels of 17-beta-E2 administered by s.c. implant or the putative membrane estrogen receptor

77 ansformation of NRP-152 cells, as assayed by s.c. tumor growth in athymic mice, whereas silencing Sma

78 s KIM6+(pCD1Ap) led to slight attenuation by s.c. inoculation but no virulence change by i.n. inocula

79 eutrophil-depleted WT mice was eliminated by s.c. injection of active, but not inactivated, CG during

80 concurrent DNA-priming strategy followed by s.c. protein boosting to again be capable of eliciting h

81 461 inhibited the growth of tumors formed by s.c. injection of mouse NIH-3T3 cells expressing oncogen

82 ansfer-based) mice were made hypertensive by s.c. infusion of angiotensin II (Ang II, 400 ng kg(-1) m

83 herapeutic vaccine were greatly increased by s.c. administration of repeated low doses in IFA.

84 els than OVA, matching the levels induced by s.c. injection of OVA/alum (SCIT).

85 ehavioral responses (scratching) produced by s.c. injection of various pruritogens in PLCbeta3- or TR

86 In contrast, s.c. or i.m. immunization usually results in the formati

87 Moreover, when tested against a CT26 s.c. xenograft tumor mouse model, significant inhibition

88 A daily s.c. dose of RgIA4 prevented chemotherapy-induced neurop

89 SSc was induced in BALB/c mice by daily s.c. injections of hypochlorous acid (HOCl).

90 Starting at age 10 mo, mice received daily s.c. injections of 10 mug/mouse of MZ-5-156.

91 Herein, we demonstrate that daily s.c. injections of either Ucn 1 or Ucn 2 to 3-week-old d

92 In vivo daily s.c. administration of 10 mug MR-409 for 3 wk dramatical

93 tivector immunization eliminated small 3-day s.c. B16 tumors and strongly inhibited the growth of mor

94 ine (CLZ) (3.8 to 15 micromol/kg twice a day s.c. for 3 days) and sulpiride (SULP) (12.5 to 50 microm

95 idol (HAL) (1.3 to 4 micromol/kg twice a day s.c. for 3 days) or olanzapine (OLZ) (4 to 15 micromol/k

96 with and without Ang 1-7 (576 microg/kg/day, s.c., Alzet pumps).

97 r disease induction, the rats received eight s.c. injections of Cit-ME on alternate days.

98 spectrally unique SERS nanoparticles either s.c. (R(2) = 0.998) or i.v. (R(2) = 0.992).

99 ficacy of these vaccines against established s.c. tumors.

100 d that HPK1(-/-) BMDCs eliminate established s.c. Lewis Lung Carcinoma more efficiently than their WT

101 cally reduced the growth of well-established s.c. tumors and significantly increased survival to high

102 a mRNA were higher in abdominal than femoral s.c. preadipocytes (P < 0.005 and P < 0.03, respectively

103 Following s.c. immunization of mice, which targets DC, we found su

104 Locomotor activity was decreased following s.c. administration of 8 and 12 mg/kg PSI but not follow

105 tudy that memory B cells generated following s.c. immunization in one footpad generate secondary resp

106 um Pi concentration occurred later following s.c. dosing (8-15 days) compared with that seen with i.v

107 enhanced transepidermal water loss following s.c. administration of IL-31.

108 ge markers, and remained organized following s.c. implantation in immunocompromised mice.

109 inally, bats that developed rabies following s.c. inoculation were significantly more likely to shed

110 produced T-dependent Ab responses following s.c. injection of 1-mum, Ag-linked microspheres, despite

111 s) in draining lymph nodes in vivo following s.c. or i.m. immunization.

112 DI5265 could be formulated at >100 mg/ml for s.c. administration and showed superior efficacy and sig

113 Furthermore, s.c. tumor rejection requires IL-17, which is produced b

114 to soluble Ag given i.p. but not to Ag given s.c. in the contralateral footpad unless LPS is coadmini

115 DC1s given s.c. migrated into draining lymph nodes, induced antigen

116 onian akinesia (0.03-0.07 mg/kg haloperidol, s.c.) or control (vehicle injection) conditions, and the

117 However, s.c. immunization induces both an IFN-gamma and an IL-17

118 HLA Tg rabbits were immunized s.c. with a mixture of the three CD4-CD8 HSV-1 gD lipope

119 Nude mice implanted s.c. with TROP-2-expressing PC3 human prostate tumor cel

120 ly as a lipid-based formulation or implanted s.c. as a cholesterol pellet.

121 cells for cytotoxicity testing or implanted s.c. into rodents to investigate scaffold immunogenicity

122 rats were either sham implanted or implanted s.c. with slow-release E2 pellets (20 ng/day for 90 days

123 ules, HLA-DQ8 transgenic mice were implanted s.c. with mini-osmotic pumps capable of continuously del

124 In s.c. tumor xenografts, tumors dominated by stromal marke

125 for ERbeta over ERalpha was administered in s.c. pellets releasing 0.04 mg/d.

126 siG12D LODER on tumor growth was assessed in s.c. and orthotopic mouse models.

127 reduced the frequency of naive ART cells in s.c. fat and increased the effector-memory populations i

128 II, and grew faster than wild-type clones in s.c. and orthotopic xenograft models.

129 wild-type (WT) controls, with no decrease in s.c. tumor growth in CD47(-/-) mice.

130 ng BCL1 lymphoma but had limited efficacy in s.c. tumors.

131 , Tbx15 is 260-fold more highly expressed in s.c. preadipocytes than in epididymal preadipocytes.

132 d immunodeficiency mice, and tumor growth in s.c. and i.p. models of MM was followed.

133 cacy in reducing the rate of tumor growth in s.c. mouse tumor xenografts.

134 hox2 (Short stature homeobox 2) is higher in s.c. than visceral fat in both rodents and humans and th

135 Finally, the isotypes were studied in s.c. and i.v. tumor xenograft models, which confirmed hI

136 e, we demonstrate that IFN-gamma-independent s.c. rejection requires both CD4(+) and CD8(+) T cells.

137 ed mice fail to respond to such inflammatory s.c. challenge in contralateral footpads, unlike lymphad

138 cs could be compatible with very infrequent, s.c. dosing while maintaining a similar level of immune

139 release of a peptide drug from an injectable s.c. depot.

140 However, cyclic di-GMP (cdGMP) injected s.c. shows minimal uptake into lymphatics/draining lymph

141 C iCSC clones (as few as 100 cells) injected s.c. into SCID/Beige mice formed tumors, and in one case

142 C57BL/6 mice injected s.c. with B16 (F10) melanoma cells demonstrated lower le

143 erance were evaluated in other mice injected s.c. with naloxone and tested for precipitated withdrawa

144 ) and the antagonist cyprodime were injected s.c. daily for in vivo studies or used for in vitro anal

145 s observed whether tumor cells were injected s.c. or i.v. and independently of the injection route of

146 C57BL/6 mice were injected s.c. with wild-type (WT), empty vector (EV), or IL-6-tra

147 When injected s.c. in mice, a single dose of microparticles sustained

148 ereas the incubation time in bats inoculated s.c. is significantly longer.

149 duced decreased tumor burden when inoculated s.c. with Lewis lung carcinoma cells.

150 n the previous study) cells were inoculated (s.c.) on the back of RAG(-/-) mice.

151 The 10 mg/kg s.c. dose evoked greater increase in extracellular serot

152 PSI 8 mg/kg s.c. or p.o., but not i.p., caused neuronal loss in the

153 type mice treated with Ac-YVAD-CMK (10 mg/kg s.c. twice daily, initiated at time of CLP) did not have

154 Systemically administered zyklophin (3 mg/kg s.c.) also prevented stress-induced reinstatement of coc

155 Systemic (1-3 mg/kg s.c.) as well as central (0.3-3 nmol intracerebroventric

156 he antagonist activity of zyklophin (3 mg/kg s.c.) lasts less than 12 h, which contrasts sharply with

157 ssed the effects of AZD8529 (20 and 40 mg/kg s.c.) on male Wistar rats trained to self-administer 20%

158 f KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.) or placebo.

159 Animals received liraglutide (0.2 mg/kg s.c.) or vehicle injections twice daily.

160 object recognition model (1, 3, and 10 mg/kg s.c.), 6s demonstrated a statistically significant respo

161 ol (0.5-5 mg/kg i.p.) or raclopride (2 mg/kg s.c.).

162 rate that aspirin-triggered LXA4 (15 mug/kg) s.c., twice a day, reduced NF-kappaB activation and leve

163 ry were administered with morphine (10mg/kg, s.c.), midazolam (2mg/kg, i.p.), and chelerythrine chlor

164 Further, acute d-amphetamine (2mg/kg, s.c.) increased extracellular glutamate concentrations i

165 nuated both by systemic nicotine (0.5 mg/kg, s.c.) and local injection of norBNI into the amygdala.

166 by clonidine pretreatment (0.03-0.15 mg/kg, s.c.) and reduced by clonidine posttreatment (0.15 mg/kg

167 ted the effects of Tat on cocaine (10 mg/kg, s.c.) induced locomotion and conditioned place preferenc

168 ne (1-9 mg/kg, s.c.) or MDPV (0.1-1.0 mg/kg, s.c.) on brain temperature homeostasis in rats maintaine

169 xamined the effects of methylone (1-9 mg/kg, s.c.) or MDPV (0.1-1.0 mg/kg, s.c.) on brain temperature

170 Atipamezole (1 mg/kg, s.c.) or vehicle (sterile saline) was administered once

171 IL-1 receptor antagonist (IL-1Ra; 100 mg/kg, s.c.) or vehicle.

172 ations pretreated with capsaicin (125 mg/kg, s.c.) the facilitatory effects of 50 muM oxo-M on BAN ac

173 PSI (8, 12 or 16 mg/kg, s.c.) was administered to female Wistar rats on 6 occasi

174 ic doses of S-ketamine (5, 10, and 25 mg/kg, s.c.), and connectivity changes 15- and 30-min post-inje

175 ne D1 receptor agonist, SKF 38393 (10 mg/kg, s.c.), indicating that it reduces hyperthermia produced

176 with a fixed dose of clonidine (0.15 mg/kg, s.c.).

177 uced by clonidine posttreatment (0.15 mg/kg, s.c.).

178 mephedrone or methylone (3.0 and 10.0 mg/kg, s.c., 3 doses) caused hyperthermia but no long-term chan

179 ilar treatment with MDMA (2.5 and 7.5 mg/kg, s.c., 3 doses) evoked robust hyperthermia and persistent

180 atal days 23-28) chronic morphine (10 mg/kg, s.c., twice daily for 5 d), induced a cAMP-dependent inc

181 of an analgesic dose of fentanyl (30 mug/kg, s.c.) was performed in vivo in male rats.

182 ol/kg, s.c.) or aminoguanidine (30 mumol/kg, s.c.) administration was evaluated.

183 fore and after 7-nitroindazole (45 mumol/kg, s.c.) or aminoguanidine (30 mumol/kg, s.c.) administrati

184 age function from Lewis lung carcinoma (LLC) s.c. tumors and lung tumor metastasis.

185 In contrast, during localized s.c. infection, IL-10 production plays a detrimental rol

186 In preliminary in vivo studies using LS174T s.c. xenograft tumor bearing mouse, selective and signif

187 , soluble IL-1 Type-1 receptors (0-4 microg, s.c.) didn't appreciably affect these behaviors.

188 ositive and EphB4-negative tumors in a mouse s.c. xenograft model.

189 ct on tumor growth was investigated in mouse s.c. tumor xenograft models.

190 or sIL-2Rbeta (0-2 microg/male Balb/c mouse; s.c.) on novelty-induced ambulatory activity and stereot

191 d over 2 days with 17beta-estradiol (10 mug, s.c.), which was repeated every 4-5 days.

192 vivo biodistribution in mice bearing Neuro2A s.c. tumors.

193 tide exenatide in rats, and a noncirculating s.c. hydrogel conjugate achieved a 150-fold extension.

194 evated in response to oral and i.p., but not s.c. footpad, immunization.

195 influenced mouse survival after i.d. but not s.c. inoculation.

196 inant infected cells following i.d., but not s.c. or i.p., inoculation.

197 ved with maximal VEGF inhibition in numerous s.c. models.

198 njection revealed that the bioavailabilty of s.c. administered rh-FcgammaRIA was 27-37%.

199 e treatment protocol mediated eradication of s.c. lesions.

200 00) had little or no effect on the growth of s.c. B16 melanomas, and only Ad-Ii-TRP-2 was able to ind

201 atis was effective at delaying the growth of s.c. B16 melanomas, orthotopic 4T1 mammary carcinomas, a

202 Irradiation of s.c. HT-1080 tumors in nude mice administered i.v. docet

203 induced obesity, with a preferential loss of s.c. fat.

204 Using an experimental model of s.c. B. anthracis infection (an encapsulated nontoxigeni

205 In this study, we used a model of s.c. human tumor xenografts in severely immunodeficient

206 ice results in the significant regression of s.c. tumors even without being pulsed with exogenous tum

207 es for infection outcome relative to that of s.c. or i.p. inoculation, including the phenotype of inf

208 enerated with topical CpG ODN at the time of s.c. immunization, suggesting a new method of enhancing

209 transferred TDLN B cells in the treatment of s.c. tumors as well as metastatic pulmonary tumors.

210 U-Omp19 s.c. delivery induces the recruitment of CD11c(+)CD8alph

211 ifferent weights implanted in the abdomen or s.c. on the back, reversibly decreases the biological bo

212 und that C57BL/6 mice given intratracheal or s.c. immunization of conidia prior to corneal infection

213 In mice bearing orthotopic or s.c. prostate cancer tumors, we show that FTY720 dramati

214 implanted orthotopically in the prostate or s.c. in the flank.

215 or cells encapsulated in alginate slabs) or s.c. enclosed in oxygenating and immunoisolating betaAir

216 Topical or s.c. CpG ODN adjuvant administration at the time of a s.

217 genicity of KRN23 following a single i.v. or s.c. dose of KRN23 in adults with XLH.

218 After i.v. or s.c. priming, partial proliferation and activation of CD

219 w-derived dendritic cells via i.p., i.v., or s.c. routes.

220 ntly PSI (8 mg/kg) was administered by oral, s.c. and i.p. routes on alternate days to separate group

221 , and intraperitoneal and subcutaneous (i.p./s.c.) routes.

222 Currently, 3 of 4 i.p./s.c.- and 2 of 4 p.o. secondary passage-inoculated cats

223 animals were vaccinated with 1.0 x 10(4) PFU s.c. at day 42 of gestation, when fetal sensitivity to R

224 Priming s.c. with 60 mug of both HIV Gag p24 vaccines elicited p

225 Study subjects also received s.c. injections of GM-CSF at a fixed dose.

226 ase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2

227 nd persisted longer in patients who received s.c. administration.

228 from RR MS patients treated with recombinant s.c. injected IFN-beta-1b revealed that they induced a s

229 Remarkably, s.c. tumor volume and lung metastasis were increased 2-f

230 Prime-boost vaccination via sequential s.c. and i.m. administration yielded greater efficacy th

231 In the in vivo setting, s.c. xenografts of WiT49 cells resembled malignant rhabd

232 d with topical applications or with a single s.c. injection of Ac2-26 revealed the anti-inflammatory

233 blished arthritis were treated with a single s.c. injection of rh-FcgammaRIA (0.2-2.0 mg/dose) given

234 papillomavirus tumor model system, a single s.c. injection of tumor-bearing mice with R-DOTAP plus h

235 expressed between visceral and subcutaneous (s.c.) fat in both humans and rodents, and in humans visc

236 y the intramuscular (i.m.) and subcutaneous (s.c.) routes with recombinant MOMP (rMOMP) from Chlamydi

237 In contrast, subcutaneous (s.c.) immunization conferred no protection against the p

238 g i.d. inoculation of the ear, subcutaneous (s.c.) inoculation of the footpad, or inoculation of the

239 and 0.73 log(10) CFU following subcutaneous (s.c.) BCG, intranasal (i.n.) BCG, or BCG s.c. + mucosal

240 ble latent infection following subcutaneous (s.c.) immunization.

241 After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients rece

242 g. the intramuscular (i.m.) or subcutaneous (s.c.) routes often stimulate weak CD8(+) T-cell response

243 Numerous small subcutaneous (s.c.) photophores (bioluminescent organs) embedded throu

244 were highly attenuated by the subcutaneous (s.c.) route.

245 Despite this, subcutaneous (s.c.) models of infection are broadly used in many field

246 e show here that survival upon subcutaneous (s.c.) VSV challenge was independent of neutralizing anti

247 (Callithrix jacchus) by i.v., subcutaneous (s.c.), and intranasal exposure routes to more closely mi

248 y saline or morphine (10mg/kg, subcutaneous, s.c.), followed 30min later by either saline or midazola

249 the strain was administered subcutaneously (s.c.).

250 1.0 x 10(5) PFU administered subcutaneously (s.c.).

251 homologous protein delivered subcutaneously (s.c.), intranasally (i.n.), i.m., or transcutaneously (t

252 ium glutamate (MSG) (4 mg/g) subcutaneously (s.c.) at 2nd,4th, 6th, 8th,10th postnatal day.

253 er intramuscularly (i.m.) or subcutaneously (s.c.) with a homologous or heterologous RABV.

254 tered intranasally (i.n.) or subcutaneously (s.c.), developed similar levels of malaria-specific IgG1

255 T cell activation in response to subsequent s.c. AML cell challenge.

256 Systemic (s.c.) injection in naive mice of cyclic AMP-phosphodiest

257 model for cystic fibrosis (CF), we show that s.c. injection or oral administration of PTC124 to Cftr-

258 disease, we have defined in this study that s.c. or intranasal sensitization followed by airway chal

259 The s.c. administration of the MOR agonist, [D-Arg2, Lys4] d

260 The s.c. implantable device allows for controlled and adequa

261 The s.c. infusion of 20-HETE shortened the tail bleeding tim

262 ivity to 1F5mIgG2a, particularly against the s.c. tumors.

263 Although the s.c. site satisfies both these criteria, the site is poo

264 neys of immunodeficient mice, as well as the s.c. implantation for preclinical drug testing, includin

265 of the dual-label (111)In-RDC018 in both the s.c. and metastatic growing tumor model.

266 In contrast, the s.c. environment is replete with IL-6 and supports the i

267 ubonic plague differs significantly from the s.c. model in multiple aspects of infection.

268 WISP2 activation in the s.c. adipose tissue, but not in visceral fat, identified

269 ient myeloid cells was also decreased in the s.c. LLC tumors.

270 sly shown to be moderately attenuated in the s.c. model, was severely attenuated in the i.d.

271 like TAM differentiation was impaired in the s.c. tumor microenvironment of mTORC1 conditional Raptor

272 onditional Raptor KO and control mice in the s.c. tumor models, although depletion of mTORC1 decrease

273 0064 has wide bioavailability, including the s.c. and oral routes.

274 antly, immunization via the i.n. but not the s.c. route elicited sporozoite neutralizing antibodies c

275 e peripheral circulation, and migrate to the s.c. immunization sites.

276 Using the s.c. B16F10 melanoma model, we found that a nontoxic dos

277 anted OVA and OVA+CAF09 administered via the s.c. or i.m. routes.

278 In summary, bats inoculated via the s.c. route are more likely to shed virus, thus increasin

279 rowth of these cells in vivo following their s.c. injection into syngeneic immunocompetent (but not i

280 g second-trimester human fetal heart tissues s.c. into the ear pinna of a SCID mouse.

281 nistration of DT-A nanoparticles directly to s.c. xenograft tumors and to the peritoneal cavity of mi

282 prolonged tumor mice survival as a tolerated s.c. agent.

283 cy confers protection against transplantable s.c. melanoma outgrowth and melanoma lung metastatic col

284 These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vit

285 Using s.c. injections of vascular endothelial growth factor or

286 e these results open the potential for using s.c. islet delivery as a treatment option for type I dia

287 Mice vaccinated s.c. with 3.8 x 10(7) CFU of the Deltacrp mutant develop

288 e microbeads resulted in highly vascularized s.c. tissue containing up to 16-fold more capillaries in

289 ) macrophages were reduced in obese Adipo-VD s.c. adipose tissue with evidence of increased immune tr

290 bone erosion) is similar in the i.p. versus s.c. immunized mice despite the presence of CD4(+) T cel

291 eceptor agonist administered twice daily via s.c. injection, improves glycemic control, often with as

292 py during these 14 sessions (5 mg/kg/day via s.c. osmotic minipump).

293 In vivo, s.c. administration of MIA-602 and MIA-690 at the dose o

294 M. ulcerans was s.c. inoculated in three consanguine mouse strains, that

295 (n = 10) or sinusitis (controls, n = 6) were s.c. co-implanted with healthy allogeneic human nasal ca

296 se tissue and bone marrow aspirates and were s.c. implanted into immunodeficient mice in the presence

297 nization route with respect to efficacy were s.c. >/= mucosal > i.m.

298 When s.c. inoculated, both EMT and non-EMT cells established

299 rameters to near background by 8 wk, whereas s.c. DC10 treatments did not affect AHR but did reduce t

300 had been diabetic for 2 mo were treated with s.c. injections of saline (control) or murine leptin (0.